NRX Pharmaceuticals (NRXP) EPS (Basic) Growth (3y) (2020 - 2026)
NRX Pharmaceuticals (NRXP) EPS (Basic) Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.31% |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 45.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.06% |
| Dec 31, 2025 | 47.16% |
| Sep 30, 2025 | 48.25% |
| Jun 30, 2025 | 41.94% |
| Mar 31, 2025 | 55.32% |
| Dec 31, 2024 | 67.89% |
| Sep 30, 2024 | 66.26% |
| Jun 30, 2024 | 77.82% |
| Mar 31, 2024 | 40.04% |
| Dec 31, 2023 | 84.65% |
| Sep 30, 2023 | 65.95% |
| Jun 30, 2023 | -70.23% |
| Mar 31, 2023 | -37.72% |
| Dec 31, 2022 | -136.21% |
| Sep 30, 2022 | -103.83% |
| Jun 30, 2022 | -54.48% |
| Mar 31, 2022 | -79.72% |
| Sep 30, 2021 | -275.17% |
| Jun 30, 2021 | -1,116.91% |
| Mar 31, 2021 | -286.29% |